# **COVID-19 Vaccine Safety Technical (VaST) Subgroup**

### Introduction

Grace M. Lee, MD MPH & Robert Hopkins, MD VaST Co-Chairs

Advisory Committee on Immunization Practices March 1, 2021

# **COVID-19 Vaccine Safety Technical (VaST) Subgroup**

## **Objectives**

- Review, evaluate, and interpret post-authorization/approval
   COVID-19 vaccine safety data
- Serve as the central hub for technical subject matter expertise from federal agencies conducting post-authorization/approval safety monitoring
- Advise on analyses, interpretation, and data presentation
- Provide updates to the ACIP COVID-19 Vaccines Working Group and the ACIP on COVID-19 vaccine safety

# **VaST Activities**

### Pre-authorization

### Jun-Dec 2020

 14 meetings to prepare for vaccine safety surveillance in the U.S.

### ACIP Recommendations

- Dec 12 –Pfizer/BioNTech
- Dec 14 1<sup>st</sup> dose administered in U.S.
- Dec 19 Moderna
- Feb 28 Janssen

### Post-authorization

### Dec 21-present

 10 meetings to review vaccine safety data



active surveillance



passive surveillance



**VA ADERS** 

VA U.S. Department of Veterans Affairs





active surveillance, passive

surveillance, case consults

individual case consults

individual



**VSD** 

Vaccine Safety

**Datalink** 







VA EHR & data warehouse





FDA Vaccine Surveillance Program



BEST Initiative
Acumen, IBM, IQVIA/OHDSI

DoD DMSS
Defense Medical
Surveillance System

large-linked database monitoring

safety monitoring timeline

### **VaST Procedures**

- Data Weekly review of available data on vaccine administration and adverse events of special interest (AESI)
- Shared learning All members, federal partners, and subject matter experts are present for presentation of data
- Independence VaST members discuss findings independently
- Reports Summary and interpretation of aggregate data provided to the ACIP Secretariat on a regular basis

# **VaST Topics Covered**

- Reviewed routine data from VAERS, v-safe, VA ADERS, VSD and CMS
- Reviewed special topics including
  - Background rates for AESI
  - Maternal immunization
  - Thrombocytopenia
  - Multisystem Inflammatory Syndrome (MIS)
  - Vaccination of persons with prior infection
- Initiated monthly sessions with additional experts to review data on vaccine safety in pregnancy

# **Outline of Today's Session**

- COVID-19 vaccine safety update
  - Maternal immunization
- COVID-19 Vaccine Safety Technical (VaST) Subgroup discussion and interpretation

### **VaST Members**

#### **Co-Chairs**

Grace Lee (ACIP)

Robert Hopkins (NVAC)

#### **ACIP Members**

Beth Bell

Matt Daley

Veronica McNally

Keipp Talbot

### **Expert Consultants**

**Kathy Edwards** 

Lisa Jackson

Martin Kulldorff

Laura Riley

Robert Schechter

Patricia Whitley-Williams

#### **CDC Co-Leads**

Lauri Markowitz

Melinda Wharton

#### **Ex Officio and Liaison Representatives**

Tatiana Beresnev (NIH)

Karen Farizo; Hui Lee Wong (FDA)

Judith Steinberg (OIDP)

Jeffrey Kelman (CMS)

Matthew Clark (IHS)

Mary Rubin (HRSA)

Fran Cunningham (VA)

Limone Collins (DoD)

### **Administrative Support**

Susan Hiers

Jared Woo

# **Acknowledgments**

- CISA
  - Karen Broder
- FDA
  - Rich Forshee
  - Steve Anderson
  - Narayan Nair
- Genesis
  - Barbara Bardenheier
- VAERS
  - John Su
- v-safe
  - Tanya Myers
  - Shin Kim

- VSD
  - Nicola Klein
  - Ned Lewis
  - Eric Weintraub
  - Michael McNeil
- Vaccine in pregnancy
  - Richard Beigi
  - Brenna Hughes
  - Denise Jamieson
  - Dana Meaney Delman
  - Titilope Oduyebo
  - LakshmiPanagiotakopoulos

- CDC Vaccine Evaluation Unit
  - Tom Shimabukuro
  - Julianne Gee
  - David Shay
  - Tom Clark
  - Stacey Martin
- Other CDC and ISO
  - Frank Destefano
  - Rita Helfand
  - Jessica MacNeil